Advertisement
STVN vs WST
Which Stock Would AI Choose? Stevanato Group (STVN) vs. West Pharmaceutical Services (WST) Stock Comparison
Key Takeaways
- STVN (Stevanato Group) is a drug containment and delivery supplier shifting toward higher-value solutions, with biologics and GLP-1 (glucagon-like peptide-1, therapies for diabetes and obesity) demand as key growth drivers.
- WST (West Pharmaceutical Services) has delivered stronger recent momentum, raising full-year guidance after double-digit revenue growth and a roughly one-third year-to-date share gain.
- Both companies benefit from the same secular tailwinds — injectable biologics, biosimilars, and GLP-1 therapies — but WST has converted those trends into faster top- and bottom-line growth in recent quarters.
- STVN trades at a more modest valuation and carries an earlier-stage mix-shift story, while WST commands a premium multiple that leaves less room for execution missteps.
- Relative performance has favored WST over recent months, though both names remain exposed to tariff, foreign-exchange, and commodity-cost pressures.
Introduction
Investors evaluating the injectable-drug supply chain often weigh STVN and WST as two distinct ways to access durable, secular demand in biologics and GLP-1 therapies. Stevanato Group is a fast-scaling European player expanding capacity and climbing the value chain, while West Pharmaceutical Services is an established, U.S.-headquartered leader with a large installed base and premium product mix. This stock comparison is most relevant to healthcare, growth, and momentum-oriented investors seeking to understand how relative performance, market positioning, and valuation differ between an emerging high-value player and an entrenched incumbent. The analysis below focuses on observable, verifiable developments from recent market activity.
STVN Overview and Recent Performance
Stevanato Group, founded in 1949 and headquartered in Italy, provides drug containment, drug delivery, and diagnostic solutions across the pharmaceutical and life sciences industries. The company is executing a deliberate transition away from lower-value bulk glass products toward higher-value solutions such as pre-fillable syringes, cartridges, and integrated delivery devices. In recent quarters, high-value solutions have grown at a double-digit pace and now represent close to half of total revenue, supported by strong demand for injectable biologics.
Recent market activity has reflected both progress and execution challenges. The company reported mid-to-high single-digit revenue growth in recent periods, with its Biopharmaceutical and Diagnostic Solutions segment outperforming while the smaller Engineering segment contracted. A notable catalyst has been European regulatory approval for a liraglutide-based therapy using the company's proprietary Alina variable-dose pen platform, strengthening its GLP-1 positioning. However, margin pressure from tariffs, foreign-currency effects, higher depreciation, and capacity ramp-up at new facilities in Italy and Indiana has weighed on sentiment, and the shares have underperformed the broader market over recent weeks.
WST Overview and Recent Performance
West Pharmaceutical Services, headquartered in Exton, Pennsylvania, is a leading provider of containment and delivery systems for injectable medicines, delivering over 41 billion components and devices annually. The company's growth is concentrated in its High-Value Product (HVP) components — premium offerings such as NovaPure and FluroTec — which now account for roughly half of total sales and have been expanding at a high-teens organic rate, driven by biologics, biosimilars, and GLP-1 elastomers.
Recent performance has been comparatively strong. In its most recent quarters, WST delivered double-digit revenue growth, a substantial jump in adjusted earnings per share (EPS, a profitability measure per share), and expanding gross and operating margins. Management has raised its full-year revenue and adjusted EPS outlook, citing momentum in high-value components and regulatory-driven customer upgrades. The stock has gained roughly one-third year to date, outpacing both its industry group and the broader market. That strength, however, has pushed its forward earnings multiple well above peer and market averages.
Trending AI Robots
Tickeron's Trending AI Robots page curates a focused selection of the platform's AI-powered trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and target universe. Because market conditions shift, only the bots best suited to the current environment are surfaced in this curated section, helping users filter signal from noise. Traders can explore bots ranging across different risk profiles and time horizons, from short-term momentum strategies to longer-horizon trend followers. Reviewing this selection can be a practical way to identify automated approaches aligned with prevailing market conditions.
Head-to-Head Comparison
The two companies share a common end-market but differ meaningfully in scale, maturity, and valuation. WST is the larger, more profitable incumbent, with roughly $3 billion in annual sales, strong free-cash-flow generation, an active share-buyback program, and a market capitalization in the tens of billions of dollars. STVN is smaller and earlier in its growth cycle, investing heavily in new capacity while carrying net debt, and it is still proving out the margin benefits of its high-value mix shift.
Growth drivers also diverge in emphasis. Both benefit from GLP-1 and biologics demand, but WST is converting regulatory tailwinds — such as European Annex 1 sterile-manufacturing standards — into near-term revenue, while STVN's catalysts, including the Alina platform, are more dependent on future adoption and facility utilization. On momentum, WST has clearly outperformed over recent months, whereas STVN has lagged the market. On risk, WST faces commodity-cost inflation, slower Standard Products growth, and a premium valuation; STVN faces tariff and currency headwinds, margin dilution from ramp-up, and elongated engineering sales cycles.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor WST at present. The stock demonstrates stronger and more consistent trend characteristics, backed by accelerating high-value product growth, expanding margins, and a series of upward guidance revisions — all of which typically rank favorably in momentum and trend-following models. STVN offers a credible longer-term mix-shift narrative, but its recent relative weakness, margin pressure, and dependence on future capacity utilization introduce greater uncertainty. This probabilistic assessment reflects current positioning rather than a definitive prediction, and relative favor can shift as new data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STVN is a Hold and WST is a Buy.
STVN in downward trend: 10-day moving average moved below 50-day moving average on October 05, 2026
The 10-day moving average for STVN crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for STVN turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 41 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
STVN moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for STVN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STVN's RSI Indicator exited the oversold zone, 22 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 56 cases where STVN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on STVN as a result. In 82 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
Following a +0.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where STVN advanced for three days, in 242 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
STVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. STVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.317) is normal, around the industry mean (4.961). P/E Ratio (38.408) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (1.538) is also within normal values, averaging (4.143). Dividend Yield (0.003) settles around the average of (0.005) among similar stocks. P/S Ratio (4.348) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
WST in upward trend: 10-day moving average crossed above 50-day moving average on September 17, 2026
The 10-day moving average for WST crossed bullishly above the 50-day moving average on September 17, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on WST as a result. In 59 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for WST just turned positive on October 15, 2026. Looking at past instances where WST's MACD turned positive, the stock continued to rise in 31 of 51 cases over the following month. The odds of a continued upward trend are 61%.
Following a +1.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where WST advanced for three days, in 201 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
The Aroon Indicator entered an Uptrend today. In 150 of 231 cases where WST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
WST broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 13 (best 1 - 100 worst), indicating outstanding price growth. WST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.261) is normal, around the industry mean (4.961). P/E Ratio (49.997) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (2.925) is also within normal values, averaging (4.143). Dividend Yield (0.002) settles around the average of (0.005) among similar stocks. P/S Ratio (7.862) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
WST | ||
|---|---|---|
OUTLOOK RATING 1..100 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 48 | |
PRICE GROWTH RATING 1..100 | 13 | |
P/E GROWTH RATING 1..100 | 20 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| STVN | WST | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | 1 day ago 54% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 52% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 65% |
| MACD ODDS (%) | 1 day ago 75% | 1 day ago 61% |
| TrendWeek ODDS (%) | 1 day ago 79% | 1 day ago 68% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 70% |
| Advances ODDS (%) | 9 days ago 80% | 1 day ago 69% |
| Declines ODDS (%) | 2 days ago 79% | 15 days ago 58% |
| BollingerBands ODDS (%) | 1 day ago 79% | 1 day ago 49% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 65% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
STVN’s FA Score shows that 0 FA rating(s) are green while WST’s FA Score has 2 green FA rating(s).
- STVN’s FA Score: 0 green, 5 red.
- WST’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
STVN’s TA Score shows that 5 TA indicator(s) are bullish while WST’s TA Score has 5 bullish TA indicator(s).
- STVN’s TA Score: 5 bullish, 5 bearish.
- WST’s TA Score: 5 bullish, 4 bearish.
Price Growth
STVN (@Pharmaceuticals: Other) experienced а +1.30% price change this week, while WST (@Pharmaceuticals: Other) price change was +2.87% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.59%. For the same industry, the average monthly price growth was -3.91%, and the average quarterly price growth was +7.47%.
Reported Earning Dates
STVN is expected to report earnings on Nov 03, 2026.
WST is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.59% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
STVN and
Correlation & Price change
A.I.dvisor indicates that over the last year, STVN has been loosely correlated with WST. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if STVN jumps, then WST could also see price increases.
| Ticker / NAME | Correlation To STVN | 1D Price Change % | ||
|---|---|---|---|---|
| STVN | 100% | +3.61% | ||
| WST - STVN | 49% Loosely correlated | +0.14% | ||
| MTD - STVN | 37% Loosely correlated | +0.40% | ||
| RGEN - STVN | 36% Loosely correlated | -0.72% | ||
| NPCE - STVN | 35% Loosely correlated | +0.69% | ||
| BRKR - STVN | 35% Loosely correlated | -3.04% | ||
More | ||||
WST and
Correlation & Price change
A.I.dvisor indicates that over the last year, WST has been loosely correlated with STVN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if WST jumps, then STVN could also see price increases.
| Ticker / NAME | Correlation To WST | 1D Price Change % | ||
|---|---|---|---|---|
| WST | 100% | +0.14% | ||
| STVN - WST | 50% Loosely correlated | +3.61% | ||
| RGEN - WST | 34% Loosely correlated | -0.72% | ||
| QDEL - WST | 33% Loosely correlated | -4.26% | ||
| NVST - WST | 32% Poorly correlated | +3.36% | ||
| CAPN - WST | 32% Poorly correlated | N/A | ||
More | ||||